General Practitioner Attendance in Proximity to HPV Vaccination: A Nationwide, Register-Based, Matched Case–Control Study
Received 8 May 2020
Accepted for publication 15 July 2020
Published 8 September 2020 Volume 2020:12 Pages 929—939
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Irene Petersen
Tina Hovgaard Lützen,1 Charlotte Ulrikka Rask,2,3 Oleguer Plana-Ripoll,4 Bodil Hammer Bech,1 Lene Wulff Krogsgaard,1 Nanna Rolving,5,6 Dorte Rytter1
1Research Unit for Epidemiology, Department of Public Health, Aarhus University, Aarhus C 8000, Denmark; 2Research Unit, Department of Child and Adolescent Psychiatry, Aarhus University Hospital, Aarhus N 8200, Denmark; 3Department of Clinical Medicine, Aarhus University, Aarhus N 8200, Denmark; 4National Centre for Register-Based Research, Department of Economics and Business Economics, Aarhus University, Aarhus V 8210, Denmark; 5University Clinic of Innovative Patient Pathways, Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg 8600, Denmark; 6DEFACTUM, Corporate Quality, Central Denmark Region, Aarhus N 8200, Denmark
Correspondence: Tina Hovgaard Lützen Research Unit for Epidemiology, Department of Public Health
Aarhus University, Bartholins Allé 2, Aarhus C 8000, Denmark
Tel +45 22410722
Aim: This study aimed to describe and compare general practitioner (GP) attendance patterns in the years surrounding HPV-vaccination among cases suspected to experience adverse events and their matched controls in order to determine if a potential larger change in GP attendance among cases was observed in temporal relation to vaccination.
Methods: Register-based, matched case–control study. Cases were defined as women referred to specialized hospital settings (HPV-centers) for suspected adverse event between June 1st 2015 and December 31st 2015 (n=1458). Information on referral was obtained from the HPV-centers directly. Each case was matched with five controls on age at vaccination, region, time of first vaccine registration and total number of doses, resulting in a total study population of 8670 girls and women. Negative binomial regression analyses were used (i) to estimate mean yearly GP contacts among cases and controls, and (ii) to further investigate the relative difference in change in GP attendance following vaccination between cases and controls.
Results: Overall, cases displayed higher GP attendance than controls from five years before vaccination up until five years after. Compared to controls, cases increased their GP attendance more in the years following HPV vaccination, corresponding to a 40% increase in the incidence rate ratios (IRR) from before to after vaccination (ratio-IRR = 1.40 [1.36; 1.44]). The change occurred in close proximity to vaccination, and the pattern was the same independently of the year of vaccination. However, for the later vaccination years cases displayed an additional increase in their GP attendance around time of extensive media attention.
Conclusion: Girls and women being referred for suspected adverse events after HPV-vaccination changed their GP attendance pattern in close proximity to their first HPV-vaccination and not solely in temporal linkage to the onset of public debate.
Keywords: HPV vaccination, general practice attendance, adverse effects, case–control
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]